As budgets become tighter and tighter, many pharmaceutical, biotechnology and device companies are having to continually re-assess the way that they are supporting research & development activities to ensure a cost-effective approach, whilst maintaining quality. Some companies have moved towards a full service strategic approach, and others have moved towards a more functional approach. Daniel Chapple at Quanticate discusses the different strategies together with some considerations for assessing each type of strategy.